GB0714941D0 - Inhibitors - Google Patents

Inhibitors

Info

Publication number
GB0714941D0
GB0714941D0 GBGB0714941.2A GB0714941A GB0714941D0 GB 0714941 D0 GB0714941 D0 GB 0714941D0 GB 0714941 A GB0714941 A GB 0714941A GB 0714941 D0 GB0714941 D0 GB 0714941D0
Authority
GB
United Kingdom
Prior art keywords
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0714941.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Priority to GBGB0714941.2A priority Critical patent/GB0714941D0/en
Publication of GB0714941D0 publication Critical patent/GB0714941D0/en
Priority to PCT/GB2008/002616 priority patent/WO2009016384A2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
GBGB0714941.2A 2007-08-01 2007-08-01 Inhibitors Ceased GB0714941D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0714941.2A GB0714941D0 (en) 2007-08-01 2007-08-01 Inhibitors
PCT/GB2008/002616 WO2009016384A2 (en) 2007-08-01 2008-07-31 Gsk-3 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0714941.2A GB0714941D0 (en) 2007-08-01 2007-08-01 Inhibitors

Publications (1)

Publication Number Publication Date
GB0714941D0 true GB0714941D0 (en) 2007-09-12

Family

ID=38529084

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0714941.2A Ceased GB0714941D0 (en) 2007-08-01 2007-08-01 Inhibitors

Country Status (2)

Country Link
GB (1) GB0714941D0 (en)
WO (1) WO2009016384A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
US20050164324A1 (en) * 2003-06-04 2005-07-28 Gygi Steven P. Systems, methods and kits for characterizing phosphoproteomes
AU2005234687A1 (en) * 2003-06-27 2005-12-08 Tel Aviv Universtiy Future Technology Development L.P. Glycogen Synthase Kinase-3 Inhibitors
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments

Also Published As

Publication number Publication date
WO2009016384A3 (en) 2009-04-09
WO2009016384A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HUS1700018I1 (en) Proteasome inhibitors
HK1176601A1 (en) Ire-1a inhibitors ire-1a
IL201379A0 (en) Inhibitors iap
DK200800103A (en) Integreret føringskant for vindturbineblad
IL200779A0 (en) Pdgfr beta-specific inhibitors
EP2200439A4 (en) Hdac inhibitors
EP2272817A4 (en) Pai-1 inhibitor
ZA201100898B (en) Novel inhibitors
GB0719997D0 (en) Portease Inhibition
ZA201102837B (en) Phosphodiestarase inhibitors
EP2222662A4 (en) Kynurenine-aminotransferase inhibitors
EP2177529A4 (en) Novel -secretase inhibitor
GB0714941D0 (en) Inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0720364D0 (en) Inhibitor
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)